Positive News SentimentPositive NewsNASDAQ:INBX Inhibrx Biosciences (INBX) Stock Price, News & Analysis $89.47 +0.37 (+0.42%) Closing price 04:00 PM EasternExtended Trading$89.68 +0.20 (+0.23%) As of 05:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Inhibrx Biosciences Stock (NASDAQ:INBX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Inhibrx Biosciences alerts:Sign Up Key Stats Today's Range$87.20▼$93.9950-Day Range$59.88▼$141.8452-Week Range$13.92▼$155.29Volume398,986 shsAverage Volume322,468 shsMarket Capitalization$1.31 billionP/E RatioN/ADividend YieldN/APrice Target$150.00Consensus RatingHold Company Overview Inhibrx, Inc., headquartered in La Jolla, California, is a clinical-stage biotechnology company focused on the discovery and development of next-generation protein therapeutics. The company’s proprietary protein engineering platform enables the design and production of multispecific and multivalent biologics with tailored binding characteristics and favorable pharmacokinetic properties. By leveraging high-throughput screening and structure-based design, Inhibrx aims to create molecules that address challenging targets in oncology, regenerative medicine and other areas of unmet medical need. The company’s lead candidate, INBRX-109, is a tetravalent agonist of the receptor tyrosine kinase ROR2 designed to stimulate tissue repair and regeneration. INBRX-109 is being evaluated in early-stage clinical studies for indications such as chronic wounds and tissue damage. In addition to its ROR2 program, Inhibrx is advancing a pipeline of preclinical assets targeting pathways including Tie2 and neuropilin-2 (NRP2), each selected for their potential to modulate angiogenesis, immune responses or fibrotic processes. Founded in 2006, Inhibrx completed its initial public offering in 2016 and trades on the Nasdaq under the ticker INBX. The company collaborates with academic research centers and strategic industry partners to accelerate the translation of its engineered proteins from discovery through clinical development. Inhibrx’s leadership team brings together expertise in molecular biology, protein engineering, translational science and regulatory affairs to drive the advancement of its therapeutic candidates toward potential regulatory approval.AI Generated. May Contain Errors. Read More Inhibrx Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreINBX MarketRank™: Inhibrx Biosciences scored higher than 53% of companies evaluated by MarketBeat, and ranked 675th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingInhibrx Biosciences has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 strong buy rating, 1 buy rating, 3 hold ratings, and 1 sell rating.Upside PotentialInhibrx Biosciences has a consensus price target of $150.00, representing about 67.4% upside from its current price of $89.62.Amount of Analyst CoverageInhibrx Biosciences has only been the subject of 3 research reports in the past 90 days.Read more about Inhibrx Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Inhibrx Biosciences are expected to grow in the coming year, from ($10.15) to ($7.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Inhibrx Biosciences is -10.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Inhibrx Biosciences is -10.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInhibrx Biosciences has a P/B Ratio of 162.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Inhibrx Biosciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted26.51% of the float of Inhibrx Biosciences has been sold short.Short Interest Ratio / Days to CoverInhibrx Biosciences has a short interest ratio ("days to cover") of 9.32.Change versus previous monthShort interest in Inhibrx Biosciences has recently increased by 8.41%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInhibrx Biosciences does not currently pay a dividend.Dividend GrowthInhibrx Biosciences does not have a long track record of dividend growth. News and Social Media3.0 / 5News SentimentN/A News SentimentInhibrx Biosciences has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Inhibrx Biosciences this week, compared to 2 articles on an average week. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Inhibrx Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders18.26% of the stock of Inhibrx Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions82.46% of the stock of Inhibrx Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Inhibrx Biosciences' insider trading history. Receive INBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inhibrx Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INBX Stock News HeadlinesInhibrx Biosciences, Inc. (NASDAQ:INBX) Given Consensus Rating of "Hold" by AnalystsMay 31, 2026 | americanbankingnews.comLifeSci Capital Reaffirms Their Buy Rating on Inhibrx Biosciences Inc (INBX)May 18, 2026 | theglobeandmail.comSpaceX is offering you shares. Don't take them.SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. But at a $1.75 trillion valuation and 266 times earnings, early institutional holders may be looking for someone to sell to. Dylan Jovine has identified a small company in Musk's supply chain that builds the power infrastructure behind Colossus - still trading at a fraction of its potential value. No IPO allocation required.June 10 at 1:00 AM | Behind the Markets (Ad)Inhibrx Biosciences, Inc.: Inhibrx Reports First Quarter 2026 Financial ResultsMay 16, 2026 | finanznachrichten.deInhibrx Biosciences (INBX) Announces Positive Interim Results From Phase 2 Portion of HexAgon StudyMay 16, 2026 | finance.yahoo.comInhibrx Reports First Quarter 2026 Financial ResultsMay 14, 2026 | prnewswire.comInhibrx Biosciences' INBRX-106 combo tops KEYTRUDA alone in phase 2 cancer studyMay 11, 2026 | msn.comInhibrx Cancer Treatment Shows High Response Rates In Head And Neck Cancer StudyMay 11, 2026 | benzinga.comSee More Headlines INBX Stock Analysis - Frequently Asked Questions How have INBX shares performed this year? Inhibrx Biosciences' stock was trading at $79.00 on January 1st, 2026. Since then, INBX shares have increased by 13.4% and is now trading at $89.62. How were Inhibrx Biosciences' earnings last quarter? Inhibrx Biosciences, Inc. (NASDAQ:INBX) announced its quarterly earnings results on Thursday, May, 14th. The company reported ($2.15) EPS for the quarter, missing the consensus estimate of ($1.68) by $0.48. When did Inhibrx Biosciences IPO? Inhibrx Biosciences (INBX) raised $102 million in an IPO on Wednesday, August 19th 2020. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Jefferies, Evercore ISI and Credit Suisse served as the underwriters for the IPO and LifeSci Capital was co-manager. Who are Inhibrx Biosciences' major shareholders? Inhibrx Biosciences' top institutional investors include Perceptive Advisors LLC (9.83%), Healthcare of Ontario Pension Plan Trust Fund (1.17%), SummitTX Capital L.P. (0.94%) and Renaissance Technologies LLC (0.34%). Insiders that own company stock include Brendan P Eckelman, Mark Lappe, Global Investors Lp Viking, Jon Faiz Kayyem and Kristiina Md Vuori. View institutional ownership trends. How do I buy shares of Inhibrx Biosciences? Shares of INBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Inhibrx Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Inhibrx Biosciences investors own include Meta Platforms (META), NVIDIA (NVDA), PayPal (PYPL), Zoom Communications (ZM), CrowdStrike (CRWD) and Moderna (MRNA). Company Calendar Last Earnings5/14/2026Today6/10/2026Next Earnings (Estimated)8/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (6d) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 For the last 6 days, INBX's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:INBX CIK2007919 Webwww.inhibrx.com Phone858-795-4220FaxN/AEmployees166Year Founded2017Price Target and Rating Average Price Target for Inhibrx Biosciences$150.00 High Price Target$150.00 Low Price Target$150.00 Potential Upside/Downside+67.5%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($8.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$140.05 million Net MarginsN/A Pretax Margin-10,014.08% Return on Equity-563.90% Return on Assets-72.32% Debt Debt-to-Equity Ratio12.58 Current Ratio6.46 Quick Ratio6.46 Sales & Book Value Annual Sales$1.30 million Price / Sales1,010.76 Cash FlowN/A Price / Cash FlowN/A Book Value$0.55 per share Price / Book162.85Miscellaneous Outstanding Shares14,670,000Free Float11,992,000Market Cap$1.31 billion OptionableOptionable Beta3.31 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:INBX) was last updated on 6/10/2026 by MarketBeat.com Staff. From Our PartnersLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredNo. You’re not imagining it…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredLive demo of Elon Musk’s AI agentJeff Brown picked Nvidia in 2016 - it's up 25,155%. He recommended Bitcoin at $240 - it's up 31,219%. Now he's...Brownstone Research | SponsoredHe Called NVIDIA at $1.10 – Now He Says, “SELL”The analyst who called NVIDIA at $1.10 now says sell. According to Alexander Green, Chief Investment Strategis...The Oxford Club | SponsoredOne hidden supplier shipped 5 billion parts to SpaceXMost investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibrx Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibrx Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
